Literature DB >> 23602683

IVF outcome in poor responders failing to produce viable embryos in the preceding cycle.

Edgardo Somigliana1, Alessio Paffoni, Andrea Busnelli, Lucia Cardellicchio, Marta Leonardi, Francesca Filippi, Guido Ragni, Luigi Fedele.   

Abstract

This study postulated that poor-responder women failing to obtain viable embryos would represent a subgroup of subjects with extremely poor prognosis. To elucidate this aspect, women in this condition over a 4-year period were retrospectively identified and their IVF outcomes in subsequent cycles were evaluated. A total of 108 women satisfied the selection criteria and underwent at least one further IVF cycle. There were 19 women excluded because they opted for a mild approach using clomiphene citrate alone, leaving 89 women for data analyses. Four women had a live birth during this first cycle, corresponding to a delivery rate per started cycle of 4.5% (95% CI 1.5-10.0%). From a public health perspective, the mean cost per delivery was € 124,540. Younger age emerged as the unique predictive factor of success. In conclusion, women with poor ovarian response failing to obtain viable embryos have extremely low chances of success in subsequent cycles. Considering the costs and risks of IVF, the appropriateness of pursuing treatments in these women is questionable. Younger women may represent a possible exception since their chances of delivery are higher.
Copyright © 2013 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23602683     DOI: 10.1016/j.rbmo.2013.02.013

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  1 in total

1.  Comparison of The Effectiveness of Clomiphene Citrate versus Letrozole in Mild IVF in Poor Prognosis Subfertile Women with Failed IVF Cycles.

Authors:  Mesut Oktem; Ismail Guler; Mehmet Erdem; Ahmet Erdem; Nuray Bozkurt; Onur Karabacak
Journal:  Int J Fertil Steril       Date:  2015-10-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.